Overview

Cefazolin PK Study 3g vs 2g

Status:
Recruiting
Trial end date:
2022-04-05
Target enrollment:
Participant gender:
Summary
Study is to characterize the safety and tolerability of cefazolin after a single IV administration in healthy subjects in a 3 g/150 mL presentation to meet the increasing clinical need for the indication of perioperative prophylaxis in this patient population weighing greater than or equal to (≥) 120 kg.
Phase:
Phase 1
Details
Lead Sponsor:
Baxter Healthcare Corporation
Treatments:
Cefazolin